Genor Biopharma

Rooted in China, laying out globally, an innovation-driven biopharmaceutical company - Genor Biopharma (Stock Code: 6998.HK) is committed to building a full value chain of biopharmaceutical innovation: a powerful dual/multi-specific antibody R&D platform adopts computer-aided technology for the development and optimization of significantly differentiated dual-target and multi-target monoclonal antibodies; the CMC process technology R&D center possesses internationally advanced process development capabilities, preclinical and clinical drug production capabilities, strong analytical testing capabilities, and a comprehensive quality system; the commercial GMP production base has continuous perfusion high-expression (20g/L), self-developed culture media, cost-effective commercial production capabilities, and a technical team highly compliant with GMP regulations. Among more than ten products of Genor Biopharma in clinical trials or regulatory filing stages, Geptanolimab Injection is planned to achieve commercialization in 2021, bringing therapeutic benefits to patients as a PD-1 product for peripheral T-cell lymphoma indications.